Biotie Therapies Selects Bracket’s CDR System(TM) for Phase 2 Trial of Treatment of Parkinson’s Disease
Cognitive function is primary endpoint
COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ — Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson’s disease and other cognitive disorders. Biotie is collaborating with the Michael J. Fox Foundation and the Parkinson Study Group to advance SYN120 into an 80 patient Phase 2 trial later this year.
The CDR System, a computerized cognitive testing method, has been used successfully in over 25 therapeutic trials including, but not limited to, Parkinson’s Disease, Alzheimer’s Disease and Mild Cognitive Impairment. It assesses the major domains of cognitive function that are vulnerable to aging, fatigue, disease, pathology, trauma, diet and pharmaceuticals. Used in more than 1,200 trials across 50 indications and available in over 30 languages, the CDR System works in all clinical settings with any patient population throughout the drug development process.
“Parkinson’s Disease affects over one million families and when I developed the CDR System over 20 years ago, it was with the intention of making a real impact in drug development, and eventually, in people’s lives,” said Professor Keith Wesnes. “I’m very pleased that Biotie has selected the CDR System for this very important trial.”
Bracket partners with sponsors and CROs to achieve greater certainty and accurate outcomes in clinical trials by providing scientific, technological and operational support, from Phase I to post approval. Bracket’s eClinical services are technology-driven solutions, applicable across many therapeutic areas. Bracket’s Scientific Services target indications that are dependent on subjective endpoints to evaluate safety, efficacy and value, and include Endpoint Reliability, Trial Enhancement Services and Computerized Cognitive Testing.
Bracket is a member of the Electronic Patient-Reported Outcome (ePRO) Consortium, a program run by the Critical Path Institute (C-Path). The collaboration works to improve the quality of patient reported outcomes, a crucial element in the drug development process.
Bracket leads the specialty services field in the U.S., U.K., Continental Europe and Japan. www.bracketglobal.com.
Contact: Annette Larkin email@example.com 703.772.6427